{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T18:14:49Z","timestamp":1761243289010,"version":"build-2065373602"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neurocognitive impairment (NCI) among people living with human immunodeficiency virus (HIV; PWH) on antiretroviral therapy (ART) may result from residual viral replication. The A5324 trial found that ART intensification with dolutegravir (DTG) with or without maraviroc (MVC) did not affect NCI in PWH. We evaluated the impact of ART intensification on peripheral virological measures during the first 12\u2005weeks of intensification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The A5324 study was a randomized, double-blind, placebo (PBO)\u2013controlled, 96-week trial of ART intensification with either dual PBO, DTG + PBO, or DTG + MVC in PWH with NCI on ART who were naive to integrase strand transfer inhibitors and MVC. At baseline and weeks 2, 4, and 12, HIV-1 RNA was measured in plasma with a low-copy assay, while HIV-1 cell-associated DNA (caDNA), cell-associated unspliced RNA (caRNA), and cell-associated 2-long terminal repeat circles (ca2LTR) were quantified from peripheral blood mononuclear cells using droplet digital polymerase chain reaction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 171 participants, 59 were randomized to dual PBO, 57 to DTG + PBO, and 55 to DTG + MVC. Changes in caDNA and caRNA and detection of plasma RNA did not differ between treatment arms over 12\u2005weeks (P &amp;gt; 0.05). Detection of ca2LTR was less frequent at weeks 2\u20134 in the DTG + MVC arm (40.4%) than in the dual-PBO (70.7%; P =0 .02) and DTG + PBO (68.4%; P = 0.03) arms. However, this difference diminished by week 12, and baseline ca2LTR detection in the DTG + MVC arm was lower than in the other groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>DTG intensification had no effect on peripheral markers of HIV-1 persistence. DTG + MVC intensification reduced ca2LTR detection at weeks 2\u20134, though this effect did not persist through week 12. These findings indicate the minimal impact of intensification on the HIV-1 peripheral reservoir, consistent with prior studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofaf594","type":"journal-article","created":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:53:13Z","timestamp":1758369193000},"source":"Crossref","is-referenced-by-count":0,"title":["Antiretroviral Therapy Intensification With Dolutegravir and\/or Maraviroc Did Not Affect HIV-1 Cell-Associated DNA, RNA, and 2\u00ad\u2013LTR Circles Over 12 Weeks"],"prefix":"10.1093","volume":"12","author":[{"given":"Jonathan C","family":"Reed","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington School of Medicine , Seattle, Washington ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke","family":"Hall","sequence":"additional","affiliation":[{"name":"Harvard T. H. Chan School of Public Health Department of Biostatistics, , Boston, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"McKhann","sequence":"additional","affiliation":[{"name":"Harvard T. H. Chan School of Public Health Department of Biostatistics, , Boston, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ginger","family":"Kwak","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington School of Medicine , Seattle, Washington ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin A","family":"Goecker","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington School of Medicine , Seattle, Washington ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W","family":"Coombs","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington School of Medicine , Seattle, Washington ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huichao","family":"Chen","sequence":"additional","affiliation":[{"name":"Harvard T. H. Chan School of Public Health Department of Biostatistics, , Boston, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jhoanna","family":"Roa","sequence":"additional","affiliation":[{"name":"DLH Corporation , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa","family":"Vecchio","sequence":"additional","affiliation":[{"name":"University of North Carolina , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric S","family":"Daar","sequence":"additional","affiliation":[{"name":"Lundquist Institute at Harbor\u2013University of California\u2013Los Angeles Medical Center , Torrance, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4571-4870","authenticated-orcid":false,"given":"Peter W","family":"Hunt","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California\u2013San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina M","family":"Marra","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington School of Medicine , Seattle, Washington ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas B","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Colorado School of Medicine , Aurora, Colorado ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0123-9913","authenticated-orcid":false,"given":"Qing","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University at Buffalo , Buffalo, New York ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shobha","family":"Swaminathan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Rutgers New Jersey Medical School , Newark, New Jersey ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0405-0991","authenticated-orcid":false,"given":"Bernard J C","family":"Macatangay","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6758-0941","authenticated-orcid":false,"given":"Gene D","family":"Morse","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University at Buffalo , Buffalo, New York ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Miller","sequence":"additional","affiliation":[{"name":"Frontier Science Foundation , Amherst, New York ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Rusin","sequence":"additional","affiliation":[{"name":"Frontier Science Foundation , Amherst, New York ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belinda","family":"Ha","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Research Triangle Park, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beverly","family":"Alston-Smith","sequence":"additional","affiliation":[{"name":"Division of AIDS, National Institutes of Health , Rockville, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Paul","sequence":"additional","affiliation":[{"name":"Department of Psychological Sciences, University of Missouri , St Louis, Missouri ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott L","family":"Letendre","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California\u2013San Diego , San Diego, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena S","family":"Spudich","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yale School of Medicine , New Haven, Connecticut ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7443-0527","authenticated-orcid":false,"given":"Alexander L","family":"Greninger","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington School of Medicine , Seattle, Washington ,","place":["USA"]},{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center , Seattle, Washington ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"2025102314044641300_ofaf594-B1","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1212\/01.WNL.0000287431.88658.8b","article-title":"Updated research nosology for HIV-associated neurocognitive disorders","volume":"69","author":"Antinori","year":"2007","journal-title":"Neurology"},{"key":"2025102314044641300_ofaf594-B2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41582-023-00813-2","article-title":"Cognitive impairment in people living with HIV: consensus recommendations for a new approach","volume":"19","author":"Nightingale","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"2025102314044641300_ofaf594-B3","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1212\/WNL.0b013e318200d727","article-title":"HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy","volume":"75","author":"Heaton","year":"2010","journal-title":"Neurology"},{"key":"2025102314044641300_ofaf594-B4","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/QAD.0000000000000096","article-title":"Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?","volume":"28","author":"Vassallo","year":"2014","journal-title":"AIDS"},{"key":"2025102314044641300_ofaf594-B5","first-page":"ofz277","article-title":"Cross-sectional and cumulative longitudinal central nervous system penetration effectiveness scores are not associated with neurocognitive impairment in a well treated aging human immunodeficiency virus-positive population in Switzerland","volume":"6","author":"Santos","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2025102314044641300_ofaf594-B6","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.3390\/v14061151","article-title":"HIV antiretroviral medication neuropenetrance and neurocognitive outcomes in HIV+ adults: a review of the literature examining the central nervous system penetration effectiveness score","volume":"14","author":"Arentoft","year":"2022","journal-title":"Viruses"},{"key":"2025102314044641300_ofaf594-B7","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1093\/cid\/ciad265","article-title":"Antiretroviral therapy intensification for neurocognitive impairment in human immunodeficiency virus","volume":"77","author":"Letendre","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025102314044641300_ofaf594-B8","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1097\/QAD.0b013e32833c9353","article-title":"Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms","volume":"24","author":"Melica","year":"2010","journal-title":"AIDS"},{"key":"2025102314044641300_ofaf594-B9","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/QAI.0b013e3181ef70fe","article-title":"Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients","volume":"55","author":"Tiraboschi","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025102314044641300_ofaf594-B10","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/cid\/ciu477","article-title":"Ing116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy\u2013naive subjects","volume":"59","author":"Letendre","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2025102314044641300_ofaf594-B11","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nm.2111","article-title":"HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects","volume":"16","author":"Buz\u00f3n","year":"2010","journal-title":"Nat Med"},{"key":"2025102314044641300_ofaf594-B12","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/infdis\/jit453","article-title":"Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial","volume":"208","author":"Hatano","year":"2013","journal-title":"J Infect Dis"},{"key":"2025102314044641300_ofaf594-B13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/cid\/cir721","article-title":"Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy","volume":"54","author":"Besson","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2025102314044641300_ofaf594-B14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/QAI.0b013e31823fd1f2","article-title":"No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy","volume":"59","author":"Gandhi","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025102314044641300_ofaf594-B15","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1128\/JVI.79.8.5203-5210.2005","article-title":"In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA","volume":"79","author":"Sharkey","year":"2005","journal-title":"J Virol"},{"key":"2025102314044641300_ofaf594-B16","doi-asserted-by":"crossref","first-page":"e2120326119","DOI":"10.1073\/pnas.2120326119","article-title":"Complex decay dynamics of HIV virions, intact and defective proviruses, and 2LTR circles following initiation of antiretroviral therapy","volume":"119","author":"White","year":"2022","journal-title":"Proc Natl Acad Sci"},{"key":"2025102314044641300_ofaf594-B17","doi-asserted-by":"crossref","first-page":"105632","DOI":"10.1016\/j.jcv.2023.105632","article-title":"Validation of digital droplet PCR assays for cell-associated HIV-1 DNA, HIV-1 2-LTR circle, and HIV-1 unspliced RNA for clinical studies in HIV-1 cure research","volume":"170","author":"Reed","year":"2024","journal-title":"J Clin Virol"},{"key":"2025102314044641300_ofaf594-B18","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/QAD.0b013e328351f627","article-title":"Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration","volume":"26","author":"Croteau","year":"2012","journal-title":"AIDS"},{"key":"2025102314044641300_ofaf594-B19","doi-asserted-by":"crossref","first-page":"e27864","DOI":"10.1371\/journal.pone.0027864","article-title":"Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected","volume":"6","author":"Guti\u00e9rrez","year":"2011","journal-title":"PLoS ONE"},{"key":"2025102314044641300_ofaf594-B20","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2012-06-436345","article-title":"The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial","volume":"121","author":"Hunt","year":"2013","journal-title":"Blood"},{"key":"2025102314044641300_ofaf594-B21","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/QAD.0000000000000810","article-title":"Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery","volume":"29","author":"Cillo","year":"2015","journal-title":"AIDS"},{"key":"2025102314044641300_ofaf594-B22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/aid.2016.0198","article-title":"Short communication: lack of effect of maraviroc intensification on blood and gut reservoir","volume":"33","author":"Tiraboschi","year":"2017","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2025102314044641300_ofaf594-B23","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1086\/650749","article-title":"Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy","volume":"50","author":"McMahon","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2025102314044641300_ofaf594-B24","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1097\/QAD.0b013e32833ef7bb","article-title":"Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy","volume":"24","author":"Yukl","year":"2010","journal-title":"AIDS"},{"key":"2025102314044641300_ofaf594-B25","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/infdis\/jiq138","article-title":"A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response","volume":"203","author":"Hatano","year":"2011","journal-title":"J Infect Dis"},{"key":"2025102314044641300_ofaf594-B26","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/jac\/dky106","article-title":"Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs","volume":"73","author":"Puertas","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2025102314044641300_ofaf594-B27","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1016\/S2352-3018(18)30040-7","article-title":"The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial","volume":"5","author":"Rasmussen","year":"2018","journal-title":"Lancet HIV"},{"key":"2025102314044641300_ofaf594-B28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1742-6405-11-33","article-title":"Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial","volume":"11","author":"Lafeuillade","year":"2014","journal-title":"AIDS Res Ther"},{"key":"2025102314044641300_ofaf594-B29","doi-asserted-by":"crossref","first-page":"e01931-17","DOI":"10.1128\/JVI.01931-17","article-title":"Maraviroc is associated with latent HIV-1 reactivation through NF-\u03baB activation in resting CD4+ T cells from HIV-infected individuals on suppressive antiretroviral therapy","volume":"92","author":"Madrid-Elena","year":"2018","journal-title":"J Virol"},{"key":"2025102314044641300_ofaf594-B30","doi-asserted-by":"crossref","first-page":"22286","DOI":"10.1038\/s41598-020-79002-w","article-title":"Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound","volume":"10","author":"L\u00f3pez-Huertas","year":"2020","journal-title":"Sci Rep"},{"key":"2025102314044641300_ofaf594-B31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e31829ed7a4","article-title":"Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing","volume":"64","author":"Greener","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025102314044641300_ofaf594-B32","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1097\/QAD.0b013e32835f2b49","article-title":"Differential penetration of raltegravir throughout gastrointestinal tissue","volume":"27","author":"Patterson","year":"2013","journal-title":"AIDS"},{"key":"2025102314044641300_ofaf594-B33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00002030-200501030-00005","article-title":"Circulating proviral HIV DNA and HIV-associated dementia","volume":"19","author":"Shiramizu","year":"2005","journal-title":"AIDS"},{"key":"2025102314044641300_ofaf594-B34","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1212\/WNL.0b013e3181bd10e7","article-title":"Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men","volume":"73","author":"Becker","year":"2009","journal-title":"Neurology"},{"key":"2025102314044641300_ofaf594-B35","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3018(19)30143-2","article-title":"Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study","volume":"6","author":"Livelli","year":"2019","journal-title":"Lancet HIV"},{"key":"2025102314044641300_ofaf594-B36","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1097\/QAI.0000000000002714","article-title":"Low-level HIV RNA in cerebrospinal fluid and neurocognitive performance: a longitudinal cohort study","volume":"87","author":"Anderson","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025102314044641300_ofaf594-B37","doi-asserted-by":"crossref","first-page":"e2210584119","DOI":"10.1073\/pnas.2210584119","article-title":"Elevation of cell-associated HIV-1 transcripts in CSF CD4+ T cells, despite effective antiretroviral therapy, is linked to brain injury","volume":"119","author":"Suzuki","year":"2022","journal-title":"Proc Natl Acad Sci"},{"key":"2025102314044641300_ofaf594-B38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/JCM.01442-20","article-title":"Automated multireplicate quantification of persistent HIV-1 viremia in individuals on antiretroviral therapy","volume":"58","author":"Jacobs","year":"2020","journal-title":"J Clin Microbiol"},{"key":"2025102314044641300_ofaf594-B39","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-019-0898-8","article-title":"A quantitative approach for measuring the reservoir of latent HIV-1 proviruses","volume":"566","author":"Bruner","year":"2019","journal-title":"Nature"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf594\/64415070\/ofaf594.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/10\/ofaf594\/64415070\/ofaf594.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/10\/ofaf594\/64415070\/ofaf594.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T18:04:55Z","timestamp":1761242695000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf594\/8266379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,9,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf594","relation":{},"ISSN":["2328-8957"],"issn-type":[{"type":"electronic","value":"2328-8957"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,29]]},"article-number":"ofaf594"}}